Word: uclaf
(lookup in dictionary)
(lookup stats)
Dates: all
Sort By: most recent first
(reverse)
ANTI-ABORTIONISTS are still making an international fuss over RU 486. In France, the pharmaceutical company Roussel Uclaf--which made the pill--almost stopped its distribution because of anti-abortion pressure. The company then reversed its decision in the face of pro-choice protests. RU 486 is now widely distributed in France, and is headed toward other Western European countries...
...right-to-life forces, the action touched off an international furor. Prochoice advocates promptly labeled the ban on the pill, called RU 486, a blow to women's rights. More than 1,000 physicians attending a meeting in Rio de Janeiro signed petitions urging that the company, Roussel Uclaf, reinstate the pill. The outcry apparently worked. By week's end, under an unprecedented order from French Minister of Health Claude Evin, the drug company, which is partly owned by the government, abruptly reversed its decision...
...pill. Both countries require that it be administered in a clinic or hospital rather than at home. To prevent casual use, the French have made it no less expensive than a surgical abortion (cost: upwards of $130). The Netherlands and England are considering approval of RU 486. Meanwhile, Roussel Uclaf, its manufacturer, has contracted with the World Health Organization to distribute the pill at low cost in developing countries...
...conglomerate, two steel companies, two chemical conglomerates, two high-technology firms and an electronics corporation. Three companies would be exempted from peremptory nationalization because of their significant foreign shareholdings: CII-Honeywell Bull (47% U.S.-owned), International Telephone and Telegraph Corp.'s French subsidiaries (99% U.S.-owned) and Roussel Uclaf Pharmaceuticals (57% West German-owned). The government will soon begin special negotiations with these firms on the terms of their eventual takeover. In general, said Mauroy, non-French shareholders would have a choice of cashing in now, selling their assets to the state next fall, or retaining a stake...
...played the part with particular bravura in Britain and France. Climaxing a long contest, they outbid the U.S.'s Sherwin-Williams Co. to win a controlling interest in Berger, Jenson & Nicholson Ltd., a major British paint producer. In France, Hoechst executives encouraged a merger of two concerns, Roussel-Uclaf and Centrale de Dynamite, which together sell about $200 million worth of Pharmaceuticals a year -or almost as much as Rhone-Pou-lenc, the French pharmaceutical leader. Hoechst has ties to both concerns and will come out owning 20% to 25% of the merged company...